7/10
Inconc.
Late treatment study
et al., medRxiv, doi:10.1101/2020.07.08.20148841v1 (Preprint)
A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxych loroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19)
2 very small studies with hospitalized patients in Taiwan.RCT with 21 treatment and 12 SOC patients. No mortality, or serious adverse effects. Median time to negative RNA 5 days versus 10 days SOC, p=0.4. Risk of PCR+ at day 14, RR 0.76, p = 0.71.This paper also reports on a small retrospective study with 12 of 28 HC Q patients and 5 of 9 in the control group being PCR- at day 14, RR 1.29, p = 0.7.
no virological cure, ↓24.0%, p=0.71
time to viral-, ↓50.0%, p=0.40, median time to PCR-
time to viral-, ↓50.0%, p=0.40, median time to PCR-